PARTICIPA

PARTICIPA

sábado, 26 de junio de 2021

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01420-3/fulltext


Enviado desde mi iPhone

No hay comentarios:

Publicar un comentario

Danos tu opinion, enriquece el post.